Teleflex's Freesolve Scaffold Shows Strong Long-Term Safety in Four-Year Study
Event summary
- Teleflex presented four-year follow-up data from the BIOMAG™-I study at EuroPCR, showing sustained safety and performance of its Freesolve™ Resorbable Magnesium Scaffold.
- The study, involving 116 patients across European centers, reported no cardiac-related events between two and four years.
- Target Lesion Failure (TLF) rate was 3.5%, with only one event occurring beyond the scaffold's resorption period.
- Results support the potential of Freesolve™ as a viable alternative to drug-eluting stents (DES).
The big picture
Teleflex's Freesolve™ Scaffold represents a shift towards bioresorbable technologies in interventional cardiology, aiming to avoid long-term stent-related adverse events. The positive four-year data positions Freesolve™ as a potential disruptor in the DES market, with ongoing trials critical for broader adoption. The focus on temporary mechanical support aligns with trends favoring minimally invasive, patient-friendly solutions in cardiovascular care.
What we're watching
- Clinical Validation
- Whether the ongoing BIOMAG™-II and pending BIOMAG™-III trials will further validate Freesolve™ as a competitive alternative to DES.
- Market Adoption
- The pace at which Freesolve™ can gain market share in CE-mark accepting countries, given its long-term safety data.
- Regulatory Pathway
- How Teleflex will navigate the regulatory landscape to potentially bring Freesolve™ to the U.S. market.
Related topics